NCT05038228View on ClinicalTrials.gov

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France

Active, not recruitingOBSERVATIONAL

Enrollment

1

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions

Atrial Fibrillation

Interventions

DRUG

Apixaban

Anticoagulant

DRUG

Rivaroxaban

Anticoagulant

DRUG

Dabigatran

Anticoagulant

DRUG

Vitamin K antagonist (VKA)

Anticoagulant

Trial Locations (1)

Unknown

Pfizer Investigator, London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY